Child ; Complement C3 ; metabolism ; Cytokinins ; analysis ; metabolism ; Female ; Humans ; Immunoglobulin A ; immunology ; Immunoglobulin G ; immunology ; Interferon-gamma ; immunology ; Interleukin-12 ; analysis ; immunology ; Interleukin-2 ; analysis ; immunology ; Male ; Peptide Fragments ; immunology ; Respiratory Tract Infections ; epidemiology ; immunology ; virology ; Secondary Prevention ; Tuberculin ; analysis

Clinically,peripheral nerve injury is common,treatment is still a clinical problem.Because of the peripheral nerve's particular dissection and the function,repair of its damage is a complex process,meticulous microsurgical technique can be used to restore nerve continuity,but the restoration of nerve function is still not satisfactory.Recently,the domestic and foreign scholars has made effort and achieved some success,particularly,the allograft nerve transplant has applied in clinical.

BACKGROUND: According to Eysenck's theory of personality, trait level belongs tolow-grade personality, which can better reflect characteristics of individual habitual behavior reaction.OBJECTIVE: To explore the correspondent relationship between generalized anxiety patient and internal personality trait through adopting Cattell's 16 Personality Factor Questionnaire (16PFQ) and Zung's Self-rating Anxiety Scale (SAS) to test generalized anxiety patients.DESIGN: A transectional sampling survey and data was compared with that of health adult norms.SETTING: Counseling clinic of out-patient in the Southwest Hospital of the Third Military Medical University of Chinese PLA.PARTICIPANTS: Totally 100 patients with generalized anxiety disorders who visited the clinical counseling clinic of out-patient in the Southwest Hospital, Third Military Medical University of Chinese PLA for the first time from August 2003 to March 2004 were included, including 40 men and 60 women.METHODS: Catell's 16PFQ was tested with Psychometric Toolbox Standard Edition V2.3 developed by the Insight Group of Peking University.The patients filled out the forms independently after the method being explained clearly by professional staff members. These 16 personality factors included warmth (reserved vs. warm; Factor A), reasoning (concrete vs.abstract; Factor B), emotional stability (reactive vs. emotionally stable;Factor C), dominance (deferential vs. dominant; Factor E), liveliness (serious vs. lively; Factor F), rule-consciousness (expedient vs. rule-conscious;Factor G), social boldness (shy vs. socially bold; Factor H), sensitivity (utilitarian vs. sensitive; Factor I), vigilance (trusting vs. vigilant; Factor L),abstractedness (grounded vs. abstracted; Factor M), privateness (forthright vs. private; Factor N), apprehension (self-assured vs. apprehensive; Factor O), openness to change (traditional vs. open to change; Factor Q1), self-reliance (group-oriented vs. self-reliant; Factor Q2), perfectionism (tolerates disorder vs. perfectionistic; Factor Q3), tension (relaxed vs. tense; Factor Q4). Standard score of each observed index was measured automatically by computer measuring system. The standard score in Zung's SAS was (65.31±7.90).MAIN OUTCOME MEASURES: Comparison of standard scores in Cattell's 16PF between anxiety group and health adult norms.tell's 16PFQ for patients with generalized anxiety disorders: Scores in A,I, L, M, O, Q4 factor of anxiety patients were higher than that of health adult norms (6.19±1.69, 5.49±1.75;6.63±1.46, 5.53±1.84;5.84±1.52,5.47 ± 1.78; 6.22 ± 1.54,5.42 ± 1.61; 8.32 ±1.54,5.48 ±1.81; 8.10 ±1.27,5.60±1.99,(t=-2.03 to -13.15, P＜ 0.05-0.01)) while scores in B, C, E, F, G H,Q1, Q2, Q3 were significantly lower (5.22±1.46, 5.93±1.97;3.48±1.68,5.51±1.75;4.86±1.60, 5.53±1.83;5.01±2.22, 5.50±1.89;4.42±1.60,5.54 ±1.66 ;4.58±1.66, 5.56±1.84 ;4.64±1.29, 5.50±1.72 ;4.73±1.80, 5.50±1.72;and F had a significantly negative correlation with scores in Zung's SAS (r=-0.273,P ＜ 0.01 ;r=-0.217,P ＜ 0.05;r=-0.217,P ＜ 0.05) while factor Q4 had a significantly positive correlation(r=0.248 ,P ＜ 0.05).CONCLUSION: The development of anxiety with high scores in C, E, F and Q4 correlates with self-personality trait. These 4 personality traits may be susceptible factors in the development of anxiety disorder and may also affect its severity.

BACKGROUND: Psychological disorders, such as depression and anxiety are relevant to pathogenesis and management of type 2 diabetes mellitus.OBJECTIVE: It was designed to investigate the influence of improving depression and anxiety in diabetes on metabolism of blood glucose.DESIGN: It was a randomized controlled comparative study.SETTING: It was conducted at the Cousulting Center for Clinical Psychology and the Endocrinology Department of Southwest Hospital Affiliated Third Military Medical University of Chinese PLA .PARTICIPANTS: Totally 43 inpatients with type 2 diabetes mellitus in the Endocrinology Department of Southwest Hospital Affiliated toThird Military Medical University of Chinese PLA were selected from October, 1999 to November 2000. All of them participated the investigation voluntarily, 24males and 19 females, with an age of 51±9 years old. They were randomly divided into 2 groups, 23 in experimental group and 20 in control group.METHODS: For experimental group, besides routine medications for diabetes, patients also Accepted anti-depression and anti-anxiety treatment, including paroxetine (20 mg, taking after breakfast everyday) and Alprazolam (0.4 mg, taking at noon, at evening and before sleep everyday). For control group, patients only Accepted routine medication for diabetes. Patients in the two groups were assessed before medication and after 4 weeks medication by Zung Self-Rating Depression Scale (SDS) and Zung Self-Rating Anxiety Scale (SAS). They were identified as depression and anxiety according to the Scales. Reduction rate of SDS/SAS score was used to assess the therapeutic effects: When the reduction rate was 50%-100%, the medication was significantly effective, when it was 25%-49% the treatment was effective, and when it was less than 25%, the treatment was noneffective.Reduction rate =(pre-treatment score-post-treatment score)/post-treatment score×100%. The fasting blood glucose level, 2-hour postprandial blood glucose level and the Glycosylated Hemoglobin (GHB, HbAl) were measured before treatment and after 4 weeks medication. Meanwhile, preprandial blood glucose level and 1-hour postprandial blood glucose level (6 times per day) were detected before treatment and at the 10th, 20th and 30th day during treatment. Reduction rate of blood glucose-(pre-treatment blood glucose level-post-treatment glucose level)/pre-treatment blood glucose level.MAIN OUTCOME MEASURES: These were main outcome measureglucose ①SDS/SAS scores, fasting blood glucose, 2-hour postprandial blood glucose and GHB before treatment and after 4 weeks treatment were measured in two group, ② and reduction rate of blood glucose.RESULTS: Six cases were omitted, 5 was in experimental group for financial pressure, intolerance to side effects of paroxetine and fears of the addiction of psychotropic drugs; the other one was in control group due to drop-out. There were 37 patients finished the investigation, 18 in experimental group and 19 in control group.①Comparison of SDS score/SAS core: After 4 weeks medication, it was observed that the post-treatment scores were significantly lower than pre-treatment scores in experimental group compared to control group[(41.05±7.05,41.88±10.57); (59.80±10.24,55.03±8.31 ), (t=2.41, 2.21, P ＜ 0.05)].②Comparison of fasting blood glucose, 2-hour postprandial blood glucose and reduction rate of blood glucose: After 4 weeks medication, the fasting blood glucose and 2-hour postprandial blood glucose in experimental group were significantly lower than those in control group(t=2.11,2.98, P ＜ 0.05-0.01)and the reduction rate of fasting blood glucose and 2-hour postprandial blood glucose in experimental group were significantly greater than those in control group (t=2.94,2.93,P ＜ 0.01). ③Comparison of GHB:After 4 weeks medication,the posttreatment GHB level in experimental group were significantly lower than pre-treatment GHB level[(8.2±2.0)%,(9.1±1.9)%, (t=2.14, P ＜ 0.05)].CONCLUSION: Anti-depression and anti-anxiety drugs not only can alleviate depression and anxiety symptoms significantly, but also can improve blood glucose metabolism. This may be attributed to an effect of anti-depression and anti-anxiety drugs in increasing the compliance of the patients to the medication for diabetes and decreasing the insulin resistance induced by negative moods.

BACKGROUND: Major depression is a subtype of depression. Application of thymoleptics alone has bad effect. It has shown from relevant studies abroad that application of fluoxetine combined with atypical antipsychotic drugs maybe an effective treating strategy.OBJECTIVE: To observe the curative effects of fluoxetine combined with olanzapine and the time of its taking effect.DESIGN: Comparative study of open clinical test with completely random sampling for the first visit outpatients SETTING: A psychological consulting clinic in a hospital of a Military Medical College of Chinese PLA.PARTICIPANTS: Totally 140 patients visiting psychological counseling outpatient clinic in the hospital were collected from January 2004 to August 2004. Inclusion criteria: According to the diagnostic criterion of depression of CCMD-3, patients with total scores of 17 items in Hamilton depression rating scale≥28and age ≥18 years old .EXclusion criteria;①slight to middle edgree of depression(Hamt≤27);②secondary depression;③convalesscent period of schizophrenia and other affective disorder caused by psychosis;④severe of unstable body diseases ,including diseases of liver,kidney,cardiae vessel,respiration,gastro-intestine,endocrine,nervous system,innune system or hematological system,cet.⑤drug or alcohol addict;⑥women in pregnancy and lactation. Totally 110 patients accorded with the inclusive criteria. Among them, there were 40 males and 70 females with the course of disease for 4 months to 5 years, aged 18 to 63 with the average (37 ± 12) years old. They all took part in the trial voluntarily. According to the date of admittance, they were divided into odd-numbered date alprazolam group in which there were 55 patients with 21 males and 34 females and double date olanzapine group in which there were 55 patients with 19 males and 36 females.METHODS: The patients were divided into 2 groups according to the date of admittance. Odd-numbered date group was alprazolam group. 0.4 mg alprazolam was given every noon and before sleep and 20 mg fluoxetine was given at a draught after breakfast every day. Even-numbered date group was olanzapine group. 2.5 mg olanzapine was given before sleep every day and 20mg fluoxetine was given at a draught after breakfast every day. The course of treatment was 6 weeks. HAMD and HAMA scores of taken were evaluated respectively before and at the end of 1st, 2nd, 4th and 6th week. Reducing score rate was used to decide effective time. Lost rate was presented as percentage. And improvement of sleep factor and somatization factor in HAMD were observed before therapy and at every observing time period after therapy.MAIN OUTCOME MEASURES: Terminus index: Comparison of HAMD,HAMA score in the two groups before therapy and at the 1st, 2nd, 4th and 6th weekend after therapy. Scores of sleep factor and anxiety somatization factor of HAMD at every observing time period in the two groups. Substitution index: lost rate in the two groups. Reducing score rate at every observing time period in the two groups.RESULTS: Lost rate in olanzapine group was significantly lower than that in alprazolam group ( P ＜ 0.05) and the effect was taken at 1 week after therapy(excellence rate 67% ) . But, scores of HAMD and HAMA at every observing time period in olanzapine group were significant lower than those in alprazolam group( P ＜ 0.01) and sleep factor and somatization factor at every observing time period improved more significantly than those of alprazolam group( P ＜ 0. 01).CONCLUSION: Small amount of olanzapine combined with fluoxetine used to treat major depression of the patients can improve sleep and anxiety body symptoms rapidly and then elevate their living quality significantly.

OBJECTIVETo evaluate the clinical effect and safety of dapoxetine in the treatment of premature ejaculation (PE).

METHODSWe randomly assigned 116 PE patients to receive dapoxetine on demand at 30 mg qd (dapoxetine group, n = 60, aged 23-49 years) or oral tamsulosin at 20 mg qd (control group, n = 56, aged 24-46 years). After 4 weeks of medication, we compared the clinical global impression of change (CGIC) , PE profile (PEP) scores, intravaginal ejaculation latency time (IELT) , and adverse reactions between the two groups of patients.

RESULTSCompared with the baseline, the IELT was remarkably prolonged after treatment both in the dapoxetine group ([0.86 ± 0.17] vs [4.32 ± 2.23] min, P < 0.05) and the control ([0.88 ± 0.15] vs [4.17 ± 2.26] min, P < 0.05), with no statistically significant difference between the two groups (P > 0. 05). The post-treatment rate of CGIC in the dapoxetine group had no statistically significant difference from that in the control (85.00% vs 82.14%, P > 0.05). In comparison with pre-treatment, the patients of both the dapoxetine and control groups showed dramatically improved scores after medication in perceived control over ejaculation (0.85 ± 0.23 vs 2.13 ± 0.97 and 0.88 ± 0.21 vs 2.06 ± 0.34, both P < 0.05), ejaculation-related personal distress (1.15 ± 0.64 vs 2.89 ± 0.26 and 1.19 ± 0.53 vs 2.82 ± 0.69, both P < 0.05), satisfaction with sexual intercourse (0.81 ± 0.33 vs 2.58 ± 0.37 and 0.79 ± 0.28 vs 2.45 ± 0.32, both P < 0.05), and ejaculation-related interpersonal difficulty (2.05 ± 0.61 vs 3.24 ± 0.35 and 2.03 ± 0.65 vs 3.18 ± 0.76, both P < 0.05), with no significant differences between the two groups (P > 0.05). The incidence of adverse reactions was significantly lower in the dapoxetine than in the control group (3.33% vs 30.36%, P < 0.05).

CONCLUSIONDapoxetine is effective for the treatment of PE, with its advantages of prolonging the intravaginal ejaculation latency time, improving the quality of sexual life, and low incidence of adverse reactions.

Adult ; Benzylamines ; administration & dosage ; therapeutic use ; Coitus ; Double-Blind Method ; Ejaculation ; Humans ; Male ; Middle Aged ; Naphthalenes ; administration & dosage ; therapeutic use ; Patient Satisfaction ; Premature Ejaculation ; drug therapy ; Serotonin Uptake Inhibitors ; administration & dosage ; therapeutic use ; Sexual Behavior ; Sulfonamides ; administration & dosage ; therapeutic use ; Treatment Outcome ; Young Adult

Actins ; metabolism ; Angiomyolipoma ; metabolism ; pathology ; surgery ; Antigens, Neoplasm ; Desmin ; metabolism ; Diagnosis, Differential ; Female ; Humans ; Leiomyosarcoma ; metabolism ; pathology ; Mediastinal Neoplasms ; metabolism ; pathology ; surgery ; Mediastinum ; pathology ; surgery ; Melanoma-Specific Antigens ; Middle Aged ; Neoplasm Proteins ; metabolism

Chordoma ; Female ; Humans ; Middle Aged ; Nasal Septum ; Nasopharyngeal Neoplasms ; Nose Neoplasms

Diagnostic Errors ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell ; diagnosis ; Lymphoma, Mantle-Cell ; diagnosis ; Middle Aged

Objective To assess the effects of 670nm LED (light-emitting diode) to protect the photoreceptor from the light-induced damage in a rat model. Methods 32 SD rats were randomly assigned to one of eight groups: untreated control group, the LED-treated control group, three groups of light-induced damage,and three groups of light-induced damage treated with LED. Light-induced damage result from exposing to constant light for 3 hours of different illuminations of 900,1800 and 2700 lx, respectively. The LED treatment (50 mW) was delivered for 30 minutes at 3 hours before the light damage and 0,24 and 48 hours after the light damage. Retinal function and morphology were measured by electroretinogram (ERG) and histopathology assay. Results The illumination of 900 lx for 3 hours did not damage the rat retina. The illumination of 1800 lx for 3 hours resulted in thinner ONL and no OS and IS. The ratio of damaged area/total retinal area was 0.48±0.12, the damaged thickness of ONL/normal ONL (L5) was 0.39±0.07,and the amplitude of ERG b wave was (431±120) μV. With the LED treatment the ratio of damaged area decreased (M6=0.17±0.12, P5/6=0.002), and the ratio of the damaged thickness of ONL also decreased (L6=0.22±0.09, P5/6<0.01), and the amplitude of ERG b wave increased to (1011±83) μV(P5/6 <0.001). The illumination of 2700 lx for 3 hours caused severed damage to the rat retina and the LED could not protect them significantly. Conclusions 670 nm LED treatment has an evident protective effect on retinal cells against light-induced damage, which may be a simple and effective therapy to prevent or to delay age-related maeular degeneration.